journal article·2018-10-31Open access

Biotinylated-lipid bilayer coated mesoporous silica nanoparticles for improving the bioavailability and anti-leukaemia activity of Tanshinone IIA

Zhe Li, Yongtai Zhang, Kai Zhang, Zimei Wu, Nianping Feng

Abstract

The oral bioavailability and anti-leukaemia activity of Tanshinone IIA (TanIIA) were enhanced by using biotinylated-lipid bilayer coated mesoporous silica nanoparticles (Bio-LB-MSNs) as a vehicle. The in vitro release of TanIIA from TanIIA@MSNs was significantly higher than that of the TanIIA powder (p < .05). The in vitro cellular uptake of TanIIA by Caco-2 was increased by loading drug into the Bio-LB-MSNs more than those of the compared nanovehicles without biotin modification. The apparent in situ permeability coefficient (Papp) of TanIIA@Bio-LB-MSNs showed nearly 2.5-, 1.6- and 1.3-fold improvement compared with the TanIIA powder, TanIIA@MSNs and TanIIA@LB-MSNs. Following oral administration of TanIIA@Bio-LB-MSNs in rats, the area under the plasma concentration–time curves (AUC) of TanIIA was 3.4-, 1.9- and 2.4-fold larger than those in the groups received a pure TanIIA powder, TanIIA@MSNs or TanIIA@LB-MSNs, indicating that drug bioavailability was enhanced by using MSNs as a vehicle, and further improved significantly through biotin modification. The in vitro anti-leukaemia activity of TanIIA was also enhanced after being loaded into nanoparticles and modification, with 50% inhibitive concentration (IC50) of NB4 cells at 6.5 μM for TanIIA@Bio-LB-MSN. In conclusion, Bio-LB-MSNs are a promising vehicle to improve the oral bioavailability and anti-leukaemia activity of the poorly water-soluble drug TanIIA.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Traditional Chinese Medicine Analysis · Ginseng Biological Effects and Applications · Plant-based Medicinal Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Sciences School of Pharmacy, Shanghai University of Traditional Chinese Medicine

School of Pharmacy, University of Auckland

Funding

National Natural Science Foundation of China

References (37)

Show source-provided references
1. Wang L, Zhou GB, Liu P, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA. 2008;105:4826–4831.
2. 10.1016/j.bcmd.2015.10.00710.1016/j.bcmd.2015.10.007 ↗
3. Wang L. Study on absorption mechanism of lipophilic components of danshen and the method of enhance absorption. Chengdu: Sichuan University; 2006.
4. Li SC, Liu JP, Zeng ZZ, et al. Study on the solubility and permeability of tanshinone II A and on the excipients increasing the solubility and permeability. Lishizhen Med Mater Med Res. 2008;19:1724–1726.
5. 10.1111/jphp.1242310.1111/jphp.12423 ↗
6. 10.4103/0973-1296.13737510.4103/0973-1296.137375 ↗
7. Li HL, Zhang ZY, Ma LL, et al. Preparation of tanshinone microemulsion and its absorption in rat intestine in situ. China J Chin Mater Med. 2007;32:1024–1027.
8. 10.1016/j.ejpb.2007.11.00610.1016/j.ejpb.2007.11.006 ↗
9. 10.1517/17425247.2016.110016510.1517/17425247.2016.1100165 ↗
10. 10.1134/S1061933X1605004510.1134/S1061933X16050045 ↗
11. 10.1016/j.bbagen.2016.07.00110.1016/j.bbagen.2016.07.001 ↗
12. 10.1016/j.jnoncrysol.2014.10.02010.1016/j.jnoncrysol.2014.10.020 ↗
13. 10.1016/j.ijpharm.2016.08.03410.1016/j.ijpharm.2016.08.034 ↗
14. 10.1016/j.colsurfb.2016.03.07610.1016/j.colsurfb.2016.03.076 ↗
15. 10.1039/C3RA44257H10.1039/C3RA44257H ↗
16. 10.1016/j.jcis.2014.08.01910.1016/j.jcis.2014.08.019 ↗
17. 10.1021/nl801596a10.1021/nl801596a ↗
18. 10.1021/nn901376h10.1021/nn901376h ↗
19. 10.1002/smll.20150211910.1002/smll.201502119 ↗
20. 10.1016/j.ijpharm.2014.12.06810.1016/j.ijpharm.2014.12.068 ↗
21. 10.1016/j.nano.2013.07.01110.1016/j.nano.2013.07.011 ↗
22. 10.1016/j.ijpharm.2012.10.01110.1016/j.ijpharm.2012.10.011 ↗
23. 10.1016/j.biomaterials.2010.01.01510.1016/j.biomaterials.2010.01.015 ↗
24. 10.1021/acsnano.5b0051010.1021/acsnano.5b00510 ↗
25. 10.1016/j.nano.2016.04.01310.1016/j.nano.2016.04.013 ↗
26. 10.1016/j.micromeso.2016.08.03710.1016/j.micromeso.2016.08.037 ↗
27. 10.1021/ja01145a12610.1021/ja01145a126 ↗
28. 10.1016/0021-9517(65)90307-610.1016/0021-9517(65)90307-6 ↗
29. 10.1016/j.ejpb.2017.09.00110.1016/j.ejpb.2017.09.001 ↗
30. 10.1016/j.canlet.2017.05.00610.1016/j.canlet.2017.05.006 ↗
31. 10.1039/C4RA12973C10.1039/C4RA12973C ↗
32. 10.1515/pac-2014-111710.1515/pac-2014-1117 ↗
33. 10.1016/j.ejps.2016.05.00310.1016/j.ejps.2016.05.003 ↗
34. 10.1016/j.micromeso.2015.08.00610.1016/j.micromeso.2015.08.006 ↗
35. Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev. 2002;5:82–85.
36. 10.1016/S1773-2247(14)50027-510.1016/S1773-2247(14)50027-5 ↗
37. 10.1016/j.bmc.2016.11.04710.1016/j.bmc.2016.11.047 ↗